Biotech Values

[DewDiligence]

Clinical / Regulatory / Litigation Calendar

[Please keep these entries up to date! See
the updating procedure at the end of this post.
Items that are out of date will be removed.]

NOTE: ANYONE MAY UPDATE THIS FILE


Edits: AIS (Anturol approved—entry deleted); BPAX (LibiGel entries deleted); GILD (Truvada sNDA in HIV prevention; 96-week Elvitegravir vs Isentress data already out—entry deleted; Quad MAA submitted); PFE (Tofacitinib PDUFA date); REGN/SNY (Zaltrap BLA in CRC withdrawn).


ABT – Bioresorbable DES: EU launch 2H12 (following reimbursement negotiations—product already approved); US launch possible in 2013 (pending clinical results).

ACHN – ACH-1625: EVR data 4Q11.
ACHN – ACH-2928: final phase-1 data at EASL Apr 2012.
ACHN – ACH-3102: file IND 1H12
ACHN – Start *some* combination trial of a PI (ACH-1625 or ACH-2684) + NS5A (ACH-2928 or ACH-3102) in 2012.

AGN – Latisse for androgenetic alopecia: phase-2 data in men and women late 2012.

AIS - Methotrexate autoinjector file NDA 1q2012

ALNY - ALN-TTR01 phase 1 data 11/2011
ALNY - ALN-TTR02 IND 2h11
ALNY - ALN-PCS phase 1 data ye2011
ALNY - ALN-RSV interim sample size analysis by ye2011, data in 2012 regardless of outcome

AMGN – Xgeva: sBLA for prevention of bone mets in CRPC PDUFA date 4/26/12; sBLA submission for bone health in non-metastatic cancer 2012-2013 pending results of phase-3 trial in breast cancer.

AMRN – AMR101 PDUFA date 7/26/12.

ANDS – See Roche.

ASTX - Dacogen for elderly AML PDUFA date 3/6/2012

AZN – Dapagliflozin: see BMY.

Bayer – Xarelto: see JNJ.
Bayer – VEGF-Trap-Eye: see REGN.

BIIB – BG-12 for MS: BLA submission 1H12.

BMY – Eliquis in AF: PDUFA date 3/28/12.
BMY – Eliquis in VTE prevention: approved in EU (3/18/11); no update on timing of possible FDA submission (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58061618 ).

BMY – Belatacept: FDA decision on BMY’s response to May 2010 CRL is on hold until BLA fixes manufacturing problems in Puerto Rico.

BMY – Yervoy in melanoma: European MAA pending (FDA approved Mar 2011).
BMY – Yervoy in melanoma brain mets: OS data from phase-2 ‘042’ trial 2011 (RR data reported at 2010 ASCO).
BMY – Yervoy in NSCLC/SCLC: OS data from phase-2 ‘041’ trial 2011 (PFS data for NSCLC reported at 2010 ASCO). Decision has been made to advance to phase-3 in NSCLC. ).

BMY – Dapagliflozin PDUFA date 1/28/12 (recently extended 3 months).

CHTP - Droxidopa in ADHD PII : Due Q1 11
CHTP - Droxidopa in NOH in Parkinsons pts only PIII Study 306 : Due Q2 11.
CHTP - CH-4051 Interim PII in RA : Due Q3 11
CHTP - Droxidopa in Fibromyalgia : Due Q4 11

ELN – Bapineuzumab: see JNJ.

GILD – 4-drug phase-2 all-oral HCV trial: SVR data early 2013.

GILD – PSI-7977: 2012 news flow in http://finance.yahoo.com/news/Pharmasset-Reports-Fiscal-prnews-1153974923.html?x=0&l=1 . (TMC435 + PSI-7977 phase-2 all-oral started 4Q11.)

GILD – Quad NDA submitted 10/27/11, awaiting decision on priority review; MAA submission 12/20/11.

GILD – Evitegravir+Cobicistat *without* Truvada: NDA 2Q12.

GILD – sNDA for Truvada in HIV prevention: submission 12/16/11, awaiting decision on priority review.

GILD – GS7340 (prodrug of tenofovir): phase-1b dose-ranging and phase-1 combo e Emtriva 2Q11.

IDIX – IDX184: phase-2b 30-day safety and VL data 1Q12. (Because of the prior clinical hold, FDA will examine the 3-day data for first 30 patients before allowing this trial to enroll additional patients.)
IDIX – IDX719 (NS5A inhibitor): file IND 4Q11.

ISIS - Mipomersin NDA 4q2011

ITMN – Pirfenidone: No specific timeline for response to FDA’s CRL of 5/4/10 requesting a new trial.

JNJ – Xarelto for ACS: sNDA submission 4Q11.

JNJ – Bapineuzumab: ‘301’/‘302’ (N. American) phase-3 trials conducted by JNJ: data in 2H12; int’l phase-3 trials conducted by PFE: data in 2014 (confirmed on PFE’s 1Q10 CC).

JNJ – Incivo (telaprevir) MAA in EU: action expected 2H11 (submission made 12/10).

JNJ – TMC435 + PSI-7977 HCV trial: see VRUS.

LGND - Promacta phase 3 data presentation AASLD 11/2011 and maybe ASH 12/2011; sNDA for HCV 2q2012
LGND - Aprela menopause NDA 2011
LGND - SCH527123 (MRK) CXCR2 antagonist p2 COPD is enrolled, data early 2012

MNTA – See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=69816156 .

MYRX - MPC3100 HSP90 inhibitor phase 1 data EORTC 11/2011

NVS – generic Copaxone: see MNTA.

PFE – Tofacitinib PDUFA date Aug 2012.

PFE – Xalkori (crizotinib) in NSCLC: EU decision mid 2012 (MAA accepted for review 8/17/11). Approved by FDA 8/26/11.

PFE – Bosutinib in CML: NDA submission late 2011; EU decision 2012 (MAA accepted for review 8/17/11).

PFE – Eliquis: see BMY.
PFE – Bapineuzumab: see JNJ.

REGN – Zaltrap BLA in CRC withdrawn 12/21/11—resubmission by SNY planneed in 1Q12. Final phase-3 VENICE study in 1st-line CRPC (Taxotere±Zaltrap) mid 2012. Roche – ANA773: start phase-2a trial 4Q11.

SNY – Aubagio for RRMS: PDUFA date Jun 2012; EU MAA submission 1Q12.

SNTA - phase 2b ganetespib NSCLC data March-April 2012 SPPI - Belinostat (CUP w/ chemo) data by ye2011 (slip)

SPPI - Belinostat NDA 2012 (timeline slip)
SPPI - Apaziquone top-line data early 2012 followed by NDA in 2012

TEVA – Copaxone litigation: see MNTA.
TEVA – Thrice-weekly formulation of Copaxone: phase-3 GALA study results expected Nov 2012.

VRTX – Telaprevir MAA in EU: see JNJ.
VRTX – Incivek + VX-222 + ribavirin/SoC phase-2 SVR data late 2011/early 2012 (interim data reported 7/26/11). (Note: this trial no longer has any arms without either SoC or ribavirin.)

VRUS – See GILD.

--
Procedure for Updating Calendar

When adding or modifying entries, please follow these steps:

1. Copy the complete text from the old calendar.

2. Make your additions or modifications, inserting new items in alphabetical order.

3. Near the top of the message, list the ticker symbols of the entries you changed (e.g. “Edits: GILD MNTA”).